FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study

Source: International Myeloma Foundation - July 24, 2015 Category: Hematology Source Type: news